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Abstract
Background: A Brazilian guideline on cervical cancer screening was released in 2011. The objective was to verify
changes in screening indicators around this period.
Methods: An audit study which sample was all screening tests performed by the public health system of Campinas
city from 2010 to 2016. Variables were absolute tests numbers, excess tests, intervals and results, by age. For trend
analysis was used Cochran-Armitage × 2 and linear regression.
Results: Were carried out 62,925 tests in 2010 and 43,523 tests in 2016, a tendency at a reduction (P = 0.001). Excess
tests were higher than 50% over the years, with a tendency at a reduction (P < 0.001). Tests performed on women
under 25 ranged from 20.2 to 15.4% in the period (P < 0.001), while in the 25–64 years age-group, it ranged from
75.1 to 80.2% (P < 0.001). In 2010 the most frequent interval was annual (47.5%) and in 2016 biennial (34.7%). There
was a tendency at a reduction in the proportion of tests performed at the first time and those with an annual
interval (P < 0.001), and also a tendency at an increase in tests with intervals equal to or greater than biannual
(P < 0.001). We observed a tendency at a reduction in LSIL and HSIL-CIN2 results (P = 0.04 and P = 0.001,
respectively), and a tendency at an increase in HSIL-CIN3 result (P = 0.02).
Conclusion: The proportion of cervical cancer screening tests performed out of the recommendation showed a
significant reduction in the period. This indicates a tendency to align cervical cancer screening in Campinas with
the standards recommended.
Background
Cervical cancer is the third most common cancer in Bra-
zilian women, although a significant disparity in rates is
observed due to different levels of social and economic
development [1–3]. Prevention is possible through vac-
cination and screening of the target population, identify-
ing women with precursor lesions and promoting timely
treatment [4]. In Brazil, screening has been encouraged
since the late ‘80s. However, there is no policy to ensure
a routine invitation to the target population. In this
scenario, screening is opportunistic, that is, tests are only
performed when women access the health system for
different reasons.
The consequence of the current screening model is that
most tests are performed when a woman seeks gynaeco-
logical or obstetric care. In this way, tests are usually per-
formed in the same women group (overscreening), while
others do not participate in screening and are at higher
risk of developing cervical cancer. This opportunistic
screening strategy has limited efficiency [4–6].
In the last decades, the expansion of the health system
in Brazil has enabled an increased provision of public
health programs, particularly in primary health care
(PHC), where screening is performed. From 2000 to
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2010, the family health strategy program (PHC) in-
creased coverage from 13.2 to 120.2 million people (7.8
to 58.5% of the population) [7]. In 2006 the first attempt
for a national cervical cancer screening guideline was
made in a technical report [8]. Only in 2011, a national
policy for screening was established with a definite rec-
ommendation of services according to the level of care,
how to obtain test quality control and how to manage
abnormal results. For the target population from 25 to
64 years old, the recommendation for the screening test
was cytology at a three-year interval after two annual
negative results [9]. The guideline was updated in 2016,
maintaining these recommendations [4]. The main limi-
tation of the guideline is that it does not suggest an invi-
tation strategy to reach the target population, preserving
the opportunistic character of the program.
The guideline of 2011 was part of a national policy for
the prevention, diagnosis, and treatment of cervical can-
cer. Cities were encouraged to adopt the guideline, and
specific financial support was established to guarantee
routine screening and early diagnosis [10].
In recent years, there has been a decrease in the abso-
lute number of screening tests in the city of Campinas,
in São Paulo state, Brazil. In 2010, about 64,000 tests
were performed, while in 2016 only about 37,000 tests
[11]. This reduction may be due to a change in the pro-
file of the woman performing the test, in the behaviour
of the professional performing the collection, or in the
way the screening is being offered. In the same period,
the epidemiologic profile did not change. Indeed, by that
time, there was an intensification of the policies for cer-
vical cancer control in Brazil, following the release of the
national recommendation. In this way, is possible that
this decrease would be related to modifications in how
screening was delivered. The objective of this study is to
evaluate if there was a tendency to align cervical cancer
screening in Campinas with the standards recommended
by the national guideline.
Methods
The paper is an audit study of trend evaluation of
screening indicators in Campinas, covering all screening
tests performed by the public health system from 2010
to 2016. The data system only registers women screened.
We do not have access to women out of the programme.
Screening tests (cytology) were taken at primary health
care, and all analysed at the university laboratory of the
Women’s Hospital Prof. Dr. José Aristodemo Pinotti
(CAISM/Unicamp).
Campinas is a city in São Paulo state with a high
Human Development Index (0.805). The population
of almost 1.2 million is mostly urban. The estimation
is that about 50% of the population has access to pri-
vate care, which means that at least 600,000 people
exclusively rely on the public health system. HPV vac-
cine started in 2014 in Brazil to girls from 9 to 14
years old, so those girls were not yet in the target
group for screening.
The study subjects were all the women who under-
went the tests in this period. The instrument of data col-
lection was the “Identification and Results Form”, which
is divided into two parts. In the first part, there is the
registration of the place of care, the identification of the
patients, the relevant clinical information, time interval
since the previous test, the purpose of the test (screen-
ing, control after abnormal result or control after treat-
ment), and age. The second part is the data on sample
quality and results. The first part is filled in by the exam-
iner (doctor, nurse or nursing technician) and the sec-
ond part by the cytologist in the laboratory. Completely
filled-out sheets are optically read, and their information
goes to the hospital information system, that provides
aggregated data reports in Excel® tables.
Interval since the previous test was filled in by the
examiner as nearly one, two, three or more than three
years. In the clinical practice, it is recorded as rounded
up to the nearest whole number. For example, a test
done at 34 months is coded as three years interval.
Some tests were excluded: those whose purpose was
identified as a previous abnormal test (control tests),
post-treatment control, and those whose time-interval
was less than one year (not qualified as screening tests).
The variables analysed were: year, age, the time interval
between tests (annual, biennial, triennial or greater than
three years), and cytological results.
The classification of the results followed Bethesda [12]
as: normal, atypical squamous cells of undetermined sig-
nificate (ASC), low-grade squamous intraepithelial lesion
(LSIL), high-grade squamous intraepithelial lesion
(HSIL), atypical glandular cells (AGC), adenocarcinoma
in situ (AIS), invasive squamous cell carcinoma (SCC),
adenocarcinoma and other neoplasms. The aggregated
data report does not differentiate “ASC possibly non-
neoplastic” from “ASC when high-grade intraepithelial
lesion cannot be excluded” (ASC-US or ASC-H). The la-
boratory distinguishes between high-grade squamous
intraepithelial lesions suggestive of cervical intraepithe-
lial neoplasia grade 2 or 3 (HSIL-CIN2/CIN3).
The study of van Ballegooijen et al. [13] was used as
the reference for the calculation of excess tests. Excess
tests were all those tests out of the national recommen-
dation: those in women aged under 25 or older than 64
years old, and those repeated less than three years since
the last test. The formula for the calculation consists of
[2/3 (b-a) + 1 / 2c + d]. Being ‘a’ the first test performed
by the woman; ‘b’, tests with an interval of 1 year; ‘c´
tests with an interval of 2 years; ‘d’ all tests performed
outside the target age group (25 to 64 years). In the
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formula, the two first annually tests were excluded by
“(b-a)”.
The variables were analysed by their frequencies. For
trend analysis over the years, the Cochran-Armitage x2
(Z) and linear regression analysis (T) was used. When
the statistic (Z or T) was positive (+), it indicated a ten-
dency at an increase of the number of tests, and when
negative (−) it indicated a tendency at a reduction of the
number of tests. The significance level adopted was 5%,
that is, P < 0.05. Analyses were performed through the
SAS Program version 9.14 for Windows.
Results
There was a significant tendency towards a reduction in
the number of tests between 2010 and 2016 (62,925 and
43,523, respectively) (P = 0.001). Also, excess tests were
higher than 50%, and over the years, a significant ten-
dency towards a reduction was identified (P < 0.001)
(Table 1).
Table 2 shows the proportion of the tests according to
the screened age-group. Tests performed on women
under 25 corresponded to 20.2% in 2010 and 15.4% in
2016, a significant tendency at a reduction (P < 0.001). In
the 25–64 years age-group, an increase in the number of
tests was observed (P < 0.001).
Table 3 shows the proportion of tests according to
the time interval. First-time examinations ranged
from 6.1 to 7.0% in the period. In 2010 the most
frequent interval was the annual (47.5%) and in 2016
the biennial (34.7%). There was a significant ten-
dency at a reduction of the tests performed for the
first time and those with an annual interval (P <
0.001), and a significant tendency at an increase of
the tests with intervals equal to or higher than bian-
nual (P < 0.001).
Table 4 shows the distribution of tests according to
the results. Normal results corresponded to almost all
the tests, varying from 97.0 to 98.0% in the period.
Among the abnormal results, the most frequent one was
ASC (1.1 to 1.6%), followed by LSIL (0.3 to 0.6%). A sig-
nificant tendency towards a reduction in the LSIL and
HSIL-CIN2 results (P = 0.04 and P = 0.001, respectively),
and a significant tendency towards an increase in the
HSIL-CIN3 result was observed (P = 0.02).
Discussion
In this audit study of cervical cancer screening indicators
in the city of Campinas, we observed a reduction in the
proportion of excess tests from 2010 to 2016, which in-
dicates better performance of the screening program. A
significant reduction in the identification of transient le-
sions and a significant increase in truly precursor lesions
were also observed. These results may indicate a positive
effect of the implementation of the cervical cancer con-
trol policy [4].
Cervical cancer screening in Campinas is opportunis-
tic. It is a common practice among these women to per-
form tests at short intervals and outside the
recommended target group (over-screening). Besides,
women without access to the health system do not par-
ticipate in screening, leading to low coverage of the tar-
get population [6].
In this study, we observed that about 2/3 of the tests
were performed at intervals lower than the recom-
mended (three years). A reduction in the proportion of
tests performed at a one-year interval was observed in
the period, and also a tendency to spacing this interval
to two or three years. An increase in the proportion of
tests performed at intervals of more than three years
may indicate a higher uptake of women who were out-
side the screening program. These results indicate com-
pliance with the recommendations. Tests performed for
the first time reduced, but also tests performed on
women younger than 25 years reduced, indicating com-
pliance with the recommended target age-group.
We observed a tendency at an increase of the propor-
tion of tests in the target age-group of 25 to 64 years,
with a tendency at a reduction of the proportion of tests
in women under 25 years, although in this age-group
this proportion remained high (15,4% of all tests in
2016). Screening women under 25 years have not shown
an impact on cervical cancer mortality [14]. Also, the in-
cidence of cervical cancer in young women is low [15],
and screening efficiency is limited [16]. The observed de-
creasing tendency in the proportion of tests in young
women may reveal more considerable attention to the
target age group, where the impact of screening is better
observed.
One consequence of performing screening tests in
young women is the high proportion of LSIL results.
Table 1 Total amount of cervical cancer screening tests and proportion of excess tests in Campinas
2010 2011 2012 2013 2014 2015 2016 Tendency/
P-value
Total of tests 62,925 58,834 60,160 50,771 53,438 48,697 43,523 T = (−)6.54
P = 0.001
Excess tests 59% 58% 57% 56% 55% 53% 50% T = (−)8.96
P < 0.001
T Test statistic, P P-value
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LSIL represents the cytological manifestation of Papillo-
mavirus (HPV) intracytoplasmic multiplication. Most of
these lesions regress spontaneously, especially in young
women [17]. Once identified by screening, they lead to
repeated examinations and overuse procedures, such as
biopsies, colposcopies, and excisional techniques, with
recognised obstetric morbidity [18, 19]. Even HSIL-
CIN2 in young women seems to behave similarly to
LSIL, with high rates of spontaneous regression [20, 21].
The reduction in the proportion of LSIL and HSIL-CIN2
results observed in our study, probably due to a decrease
in the proportion of screened young women, indicates
an improvement in program efficiency.
HSIL-CIN3 is considered the true precursor lesion in
all age groups [17]. During the implementation of an
organised screening program, an increase in the identifi-
cation of precursor lesions is expected, which are the
prevalent lesions that have not yet been identified. With
time, as these lesions are treated, the number of precur-
sor lesions identified falls, as well as the number of inva-
sive cancers [4].
In our study, we observed a tendency at an increase of
the proportion of HSIL-CIN3, although at a very low
frequency (about 0.1% of the total number of exams),
and without a significant change in the outcome of inva-
sive results. Possibly, this result is associated to the in-
crease of the number women of the target population,
either by increasing the coverage of women between 25
and 64 years-old or by the rise in the number of tests
performed in women with more than three-year interval.
This would indicate an improvement in program effi-
ciency. If this hypothesis is correct, in a few years a re-
duction of precursor lesions may be observed, with a
consequent decrease in the incidence of cancer.
The main result of this study was a significant reduc-
tion in the tests performed in excess. There is a sugges-
tion that opportunistic screening is not as cost-effective
as organised screening. In opportunistic screening, the
reduction in incidence and mortality rates is not as pro-
nounced as in organised screening, and health resources
are poorly optimised [5, 6, 18, 22]. Reducing the number
of excess tests means reducing screening program costs
and enhancing women’s access.
The implementation of an organised screening pro-
gram is a complex task in public health. The critical
component is an invitation system to the target
Table 2 Cervical cancer screening tests in Campinas according to the age of the women
2010 2011 2012 2013 2014 2015 2016 Tendency/
P-value
< 25 years 12,697 20.18% 11,507 19.56% 10,981 18.25% 9060 17.84% 9541 17.85% 8214 16.87% 6708 15.41% Z = (−)22.4
P < 0.001
25–64 years 47,275 75.13% 44,449 75.55% 46,036 76.52% 38,975 76.77% 41,235 77.16% 38,107 78.25% 34,882 80.15% Z = 21.2
P < 0.001
> 64 years 2953 4.69% 2878 4.89% 3143 5.22% 2736 5.39% 2662 4.98% 2376 4.88% 1933 4.44% Z = (−)1.3
P = 0.200
Total 62,925 58,834 60,160 50,771 53,438 48,697 43,523
Z Test statistic, P P-value
Table 3 Cervical cancer screening tests in Campinas according to the interval of the tests
Year/
Interval
2010 2011 2012 2013 2014 2015 2016 Tendency/
P-value
First test 4424 7.03% 4109 6.98% 3963 6.59% 3304 6.51% 3575 6.69% 3266 6.71% 2635 6.05% Z = (−)5.75
P < 0.001
1 year 29,865 47.46% 26,113 44.38% 26,233 43.61% 19,977 39.35% 19,886 37.21% 17,096 35.11% 13,169 30.26% Z = (−)67.26
P < 0.001
2 years 16,437 26.12% 16,257 27.63% 16,590 27.58% 15,754 31.03% 16,850 31.53% 15,687 32.21% 15,100 34.69% Z = 36.79
P < 0.001
3 years 5353 8.51% 5420 9.21% 5837 9.70% 5220 10.28% 5806 10.86% 5714 11.73% 5934 13.63% Z = 30.01
P < 0.001
> 3 years 5212 8.28% 5166 8.78% 5641 9.38% 5082 10.01% 5791 10.84% 5567 11.43% 5478 12.59% Z = 28.15
P < 0.001
Not informed 1634 2.60% 1769 3.01% 1896 3.15% 1434 2.82% 1530 2.86% 1367 2.81% 1207 2.77% Z = (−)0.05
P = 0.959
Total 62,925 58,834 60,160 50,771 53,438 48,697 43,523
Z Test statistic, P P-value
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population. This invitation would support equity on ac-
cess and higher coverage. In low and middle-income re-
gions, usually a population-based registry is absent, and
screening is opportunistic. Other strategies towards an
increase in the efficiency of the program should be
developed.
In 2011 the Ministry of Health, in collaboration with
the National Cancer Institute and the academy, all
joined to improve screening performance by primary
health care, which is provided by municipalities. The
positive results showed in this study needs to be viewed
in this context, as Campinas can be considered an index
city in the implementation of public health programs. As
a final result, reducing the number of unnecessary tests
allows the entry of other individuals into the program,
using the same resources. Additional efforts must be
made to increase coverage of the target population.
The main strength of this study is the fact that it
enacted a population-based assessment since all the tests
performed by the public health in Campinas in the
period could be analysed. In addition, it has benefited
from the existence of a good quality information system.
The study did not propose to analyse the data of private
health care since it intended to evaluate only the per-
formance of the public policies in the region. It is not
possible to assess whether private care screening is also
complying with the guidelines. We also do not know
what is happening in women without access to the pro-
gram, as it is an opportunistic screening, so our conclu-
sion refers only to women included. Because data were
aggregated and not linked to other information systems,
it was not possible to confirm histopathological results.
Since the period analysed was short (2010 to 2016), it is
not yet possible to say whether the results will translate
into improvements in incidence and mortality rates.
Conclusions
Audits in health programs by using performance indica-
tors are an essential step in quality control. In this study,
we observed that the proportion of cervical cancer
screening excess tests performed in the public health
system of Campinas showed a significant reduction be-
tween 2010 and 2016. This result indicates a tendency to
the adequacy of the program to the current guideline,
towards an organised screening program.
Abbreviations
Adenoca: Adenocarcinoma; AGC: Atypical glandular cells;
AIS: Adenocarcinoma in situ; ASC: Atypical squamous cells of undetermined
significate; ASC-H: ASC when high-grade intraepithelial lesion cannot be ex-
cluded; ASC-US: ASC possibly non-neoplastic; HPV: Human Papillomavirus;
Table 4 Cervical cancer screening tests in Campinas according to the results
2010 2011 2012 2013 2014 2015 2016 Tendency/
P-value
Normal 61,006 96.95% 57,380 97.53% 58,857 97.83% 49,728 97.95% 52,213 97.71% 47,459 97.46% 42,257 97.09% Z = 1.30
P = 0.072
ASC 1031 1.64% 843 1.43% 630 1.05% 544 1.07% 723 1.35% 796 1.63% 712 1.64% Z = 1.62
P = 0.106
LSIL 382 0.61% 263 0.45% 187 0.31% 134 0.26% 187 0.35% 173 0.36% 268 0.62% Z = (−)2.07
P = 0.039
HSIL-CIN2 113 0.18% 98 0.17% 69 0.11% 36 0.07% 68 0.13% 46 0.09% 63 0.14% Z = (−)3.28
P = 0.001
HSIL-CIN3 85 0.14% 46 0.08% 51 0.08% 32 0.06% 74 0.14% 57 0.12% 70 0.16% Z = 2.32
P = 0.02
AGC 28 0.04% 23 0.04% 11 0.02% 7 0.01% 9 0.02% 12 0.02% 21 0.05% Z = (−)0.96
P = 0.337
AIS 1 0.00% 4 0.01% 2 0.00% 0 0.00% 0 0.00% 0 0.00% 1 0.00% Z = (−)1.46
P = 0.143
SCC 7 0.01% 1 0.00% 6 0.01% 8 0.02% 10 0.02% 5 0.01% 5 0.01% Z = 1.21
P = 0.228
Adenoca 8 0.01% 9 0.02% 2 0.00% 5 0.01% 6 0.01% 1 0.00% 3 0.01% Z = (−)1.68
P = 0.094
Other neoplasias 0 0.00% 0 0.00% 0 0.00% 0 0.00% 2 0.00% 1 0.00% 0 0.00% Z = 1.36
P = 0.173
No result 264 0.42% 167 0.28% 345 0.57% 277 0.55% 146 0.27% 147 0.30% 123 0.28% Z = (−)4.37
P < 0.001
Total 62,925 58,834 60,160 50,771 53,438 48,697 43,523
Z Test statistic, P P-value, ASC atypical squamous cells of undetermined significate, LSIL low grade squamous intraepithelial lesion, HSIL-CIN2 high grade squamous
intraepithelial lesions suggestive cervical intraepithelial neoplasia grade 2, HSIL-CIN3 high grade squamous intraepithelial lesions suggestive cervical intraepithelial
neoplasia grade 3, AGC atypical glandular cells, AIS adenocarcinoma in situ, Adenoca Adenocarcinoma, SCC invasive squamous cell carcinoma
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HSIL-CIN2: High-grade squamous intraepithelial lesions suggestive cervical
intraepithelial neoplasia grade 2; HSIL-CIN3: High-grade squamous
intraepithelial lesions suggestive cervical intraepithelial neoplasia grade 3;
LSIL: Low-grade squamous intraepithelial lesion; P: P-value; SCC: Invasive
squamous cell carcinoma; T: Test statistic; Z: Test statistic
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